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Many infections favor or are directly implicated with lipid metabolism perturbations and/or increased risk of coronary heart dis-
ease (CHD). HIV itself has been shown to increase lipogenesis in the liver and to alter the lipid proﬁle, while the presence of unsafe
habits, addiction, comorbidities, and AIDS-related diseases increases substantially the risk of cardiovascular disease (CVD) in the
HIV-infected population. Antiretroviral therapy reduces such stimuli but many drugs have intrinsic toxicity proﬁles impacting on
metabolism or potential direct cardiotoxicity. In a moment when the main guidelines of HIV therapy are predating the point when
to start treating, we mean to highlight the contribution of HIV-1 to lipid alteration and inﬂammation, the impact of antiretroviral
therapy, the decisions on what drugs to use to reduce the probability of having a cardiovascular event, the increasing use of statins
andﬁbratesinHIV-1infectedsubjects,andﬁnally theswitchstrategies,thatbalance eﬀectiveness andtoxicity tomovethedecision
to change HIV drugs. Early treatment might reduce the negative eﬀect of HIV on overall cardiovascular risk but may also evidence
the impact of drugs, and the ﬁnal balance (reduction or increase in CHD and lipid abnormalities) is not known up to date.
1. CHDandInfections
By the turn of the last century, medicine abandoned the link
between infection, metabolic disorders, and atherogenesis
because it did not ﬁt in with the trends of the medical
establishment convinced that chronic diseases such as heart
disease must be multifactorial, degenerative, and nonin-
fectious. Today, many patients with heart disease do not
have the classic risk factors such as hypercholesterolemia,
hypertension, smoking, or obesity; so it is not inconsistent
that infection might underlie such damage.
It is now generally recognised that cytokines, especially
TNF, interleukin-1, and interleukin-6, which mediate the
host acute-phase response to infection and inﬂammation,
also mediate changes in lipid metabolism.
Several studies have addressed the possible role of infec-
tious agents, both bacteria and viruses, in the pathogenesis
of coronary heart disease and atherosclerosis [1, 2]. The
conceptofpathogenburdenasariskfactorforCHDwasﬁrst
introduced by Epstein and his collaborators [3].
Both acute and chronic infections could play a role
in the development of atherosclerosis and CHD. Acute
infections (i.e., Coxsackie B viruse-induced myocarditis)
could trigger acute cardiovascular events, and an acute
respiratory infection during the 2 preceding weeks has been
shown to be a risk factor for AMI in people with no history
of classic risk factors [4].
Chronic infections may actively participate in the
atherosclerotic process, leading to continuous low-level
production of cytokines and thus to an atherogenic lipid
proﬁle, increasing triglyceride and total cholesterol, and
lowering HDL concentrations [5]. Via their eﬀect on lipid
and glucose metabolism, chronic infections might also be
related with obesity and the metabolic syndrome [6].
People infected with multiple pathogens, such as HSV-
1, HSV-2, CMV, H. pylori, C. pneumoniae, and hepatitis
A virus have high C-reactive protein rates as a marker
of inﬂammation—a major relative risk factor for coronary
artery disease [7]—and serological association between
enteroviruses and human CHD has been suggested [8].2 Cholesterol
Finally, mycobacterial diseases share interesting connec-
tions to heart disease because the pathogenesis of tuber-
culosis depends on cholesterol and atypical tuberculosis
caused elevation of C-reactive Protein, interleukin-6, and
homocysteine 2 [9].
2. DyslipidemiaandHIV-1 Infection
2.1. In Vitro Studies. HIV-1 infection causes a speciﬁc
pattern of dyslipidemia, resulting from a combination of
increased production and decreased clearance of lipopro-
teins. Molecular mechanisms responsible for the numerous
lipid-related disorders in HIV-infected individuals are not
well understood. Adipose tissue hosts multiple cell types
includingmonocytes,macrophages,endothelialandvascular
smooth muscle cells. These immune cells are functionally
active in the adipose tissue and produce numerous cytokines
and other regulatory factors that inﬂuence lipid homeostasis,
regulation of steroid hormones, prostaglandin, and fat-
soluble vitamins. These factors also control storage of excess
lipids and triglycerides (either normal and abnormal fatty
acids) present in the circulation. Many infectious agents
including HIV-1 have profound impact on adipocytes which
become dysfunctional and cannot store most lipids—that is,
triglycerides—properly.
Rasheed et al. [10] present the ﬁrst direct evidence
that HIV replication alone in human T-cells, without any
inﬂuence of antiviral drugs or other factors, can stimulate
the production of novel cellular enzymes and proteins that
enhance fatty acid synthesis, increase the quantity of low
density lipoproteins, secrete triglycerides, alter the lipid
transport and metabolism, and oxidize lipids. This ﬁnding
leads us to a new concept in HIV-1 pathogenesis. One of the
most essential biological processes involved in dyslipidemia
and lipodystrophy syndrome is the accumulation of lipids
and disproportionate distribution of tissue-associated fats
due to the enhanced fatty acid synthesis. Since kinases and
enzymes activate most cellular functions including lipid
synthesis, Rasheed ﬁrst analyzed the functional signiﬁcance
of these proteins in HIV-infected cells in comparison with
those expressed in the uninfected control cells.
They discovered that of the 18 diﬀerentially expressed
proteins in HIV-infected cells, six enzymes/kinases were
expressed exclusively in HIV-infected cells (CO3, P3C2B,
KPCB, FAS, ACSL1, and GPX1) and one isomerase (PDIA3)
wasslightlydownregulatedafterchronicHIVinfection.They
conclude that HIV-1 replication alone (i.e., without any
inﬂuence of antiviral drugs or other human genetic factors)
can induce novel cellular enzymes and proteins that are
signiﬁcantly associated with biologically relevant processes
involved in lipid synthesis, transport, and metabolism (P =
.0002–.01). This is the ﬁrst direct evidence that HIV-1
modulates the production of proteins that are signiﬁcantly
involved in disrupting the normal metabolic pathways of
lipids. However, the study presents several possible biases
becauseitisnotcleariftheresultwouldbethesamewithreal
cells; besides only X4 virus was studied which may not reﬂect
theinvivosituation,mainlycharacterisedbyR5-tropicvirus.
Furthermore, polybrene was used to infect the cells, which
artiﬁcially helps to bypass surface binding and entry by the
virus.
Translationalandclinicalstudiesonthenewlydiscovered
proteins may now shed light on how some of these proteins
may be useful for early diagnosis of individuals who might
be at high risk for developing lipid-related disorders. The
target proteins could then be used for future studies in
the development of inhibitors for preventing lipid-metabolic
anomalies.
2.2. In Vivo Studies. Hellerstein et al. [11]m e a s u r e dd e
novo lipogenesis in three groups of patients (HIV-infected
with history of weight loss, asymptomatic HIV-infected, and
uninfected males) and found that hepatic lipogenesis was
three to fourfold higher in the ﬁrst group compared with
seronegative controls (P<. 05). The authors concluded that
HIV infection was associated with abnormal fat anabolism.
Riddler et al. [12] evaluated changes in serum cholesterol
associated with HIV infection and subsequent antiretroviral
therapy, testing saved blood samples on 50 of 517 male
seroconvertersfromtheMulticenterAIDSCohortStudy.The
outcome measures were changes in total cholesterol (TC),
high-density lipoprotein cholesterol (HDL-c), and low-
density lipoprotein cholesterol (LDL-c). These parameters
were evaluated at six time points over a period of 12 years.
After HIV seroconversion, they noted signiﬁcant declines
in TC, HDL-c, and LDL-c. Following the initiation of
HAART, increases in TC and LDL-c to slightly above pre-
seroconversion levels were seen. The authors concluded that
HIV infection alone results in substantial decrease in TC,
HDL-c, and LDL-c. They postulated that the posttreatment
elevations in TC and LDL-c probably represent a return to
preinfection lipid levels.
Moreover, many additional factors may inﬂuence athero-
genesis and CVD, such as AIDS-related infections [13]
or the fact that certain “classical” vascular risk factors
are overrepresented in the HIV-infected population (i.e.,
cigarette smoking). On the other hand, recent studies have
shown that, similarly to the observation made in the general
population, HCV coinfection seems to be associated with
lower blood levels of cholesterol in HIV patients receiving
ART [14].
3. CardiacRisk andHIVInfection
Prior to the advent of HAART, infections and tumours were
the prevalent causes of cardiovascular damage in HIV-1
infected subjects (pericarditis, miocarditis, endocarditis, and
cardiac involvement in AIDS-related tumours). With the
advent of HAART and the subsequent longer survival, the
most common cardiovascular disease is ischemic disease
[15].
However, it is not so clear to what extent antiretroviral
therapy may increase or decrease the risk of cardiovascular
disease (CVD). CVD, indeed, is more common in HIV-
infectedpatientsthanHIVnegative,mostlyduetothehigher
prevalence of CV risk factors like metabolic abnormalitiesCholesterol 3
(dyslipidemia and insulin resistance) and drug consumption
(tobacco, alcohol, cocaine) [16, 17]. Moreover, HIV infects
smooth muscle cells in vivo promoting inﬂammation [18]
and ACTG 5152s showed that untreated HIV infection is
associated with endothelial dysfunction, and ART restores
the endothelial damage [19, 20].
The diﬃculties in determining the cardiac risk among
HIV-infected patients have largely been due to the lack of
matched controls and to small sample sizes.
4. CardiacRisk andAntiretroviralTherapy
Although some drugs may be more harmful than others in
increasing CVD risk, it is now clear that any therapy is better
than no therapy.
In the largest trial of intermittent treatment, the SMART
study, patients assigned to the intermittent therapy arm had
a higher incidence of cardiovascular disease [21]. In the
STACCATOstudy,theinterruptionoftherapywasassociated
with increases in markers of endothelial dysfunction and
inﬂammation contributing to the development of cardiovas-
cular disease [22].
When choosing the drugs to build an antiretroviral
regimen, however, not every drug or class of drugs is
equivalent in terms of impact on the CVD risk.
The Data Collection on Adverse Events of Anti-HIV
Drugs (D:A:D) investigators reported an increased relative
rate (RR) of myocardial infarction (MI) with the cumulative
use of protease inhibitors (RR per year of exposure, 1.16
[95% conﬁdence interval {CI}, 1.10–1.23]) but not of
nonnucleoside reverse transcriptase inhibitors (RR per year
of exposure, 1.05 [95% CI, 0.98–1.13]) [23]. In a subse-
quent analysis focusing on nucleoside reverse transcriptase
inhibitor use, an unexpected increased risk of MI was found
with recent use of abacavir (RR, 1.90 [95% CI, 1.47–2.45])
and didanosine (RR, 1.49 [95% CI, 1.14–1.95]), but not with
cumulative use [24].
Many trials and nonsponsored studies have assessed the
eﬃcacy and the lipid proﬁle of all the approved antiretro-
virals and nowadays the metabolic impact of a new drug is
considered as important as its potency.
The STEAL study evaluated the incidence of CVD over
96 weeks in patients treated with abacavir plus lamivudine
(ABC/3TC) versus tenofovir plus emtricitabine (TDF/FTC).
PatientsassignedtotheABC/3TCarmhadsigniﬁcantlymore
cardiovasculareventsbutunfortunatelypatientsinABC/3TC
had a heavier history of risk factors than patients assigned to
TDF/FTC [25].
The BICOMBO study, another randomized trial of
switching to the thymidine analogue-sparing ﬁxed dose
combinations (FDCs), showed only one case of myocardial
infarction in a younger population with a lower baseline
Framingham score [26].
The ACTG 5202 study, a multicenter, randomized,
blinded equivalence study compared antiviral activity, safety,
and tolerability of ABC/3TC and TDF/FTC given with
efavirenz or ritonavir-boosted atazanavir for the initial
treatment of HIV-1 infection, followed for 96 weeks. A total
of 1858 eligible patients were enrolled in the study from
September 2005 to November 2007. This analysis includes
data from 797 patients with a screening HIV-1 RNA level of
100,000copies/mL or more. At week 48, fasting lipid levels
had increased more in the patients who received ABC/3TC
than in the patients who received TDF/FTC (median change
in TC level: 34 versus 26mg/dL, P<. 001; HDL-c level:
9v e r s u s7 m g / d L ,P = .05; and triglyceride (TG) level:
25 versus 3mg/dL, P = .001). There was no signiﬁcant
diﬀerence between groups in the change in the ratio of TC:
HDL-c (median, −0.2 for both groups; P = .50) [27].
The GEMINI study, a 48-week, multicenter, open-label
study, conﬁrmed the noninferiority of a TDF/FTC backbone
plus saquinavir/ritonavir (SQV/r) 1000mg/100mg twice a
day (n = 167) versus TDF/FTC plus lopinavir/ritonavir
(LPV/r) 400mg/100mg twice a day (n = 170) in treatment-
naive HIV-1-infected adults.
T h er a t ea n ds e v e r i t yo fa d v e r s ee v e n t sw e r es i m i l a ri n
both groups. There were no signiﬁcant diﬀerences in the
median change from baseline between arms in plasma lipids
except for triglyceride levels, which were signiﬁcantly higher
in the LPV/r arm at week 48 [28].
KLEAN is an open-label, noninferiority study includ-
ing 878 antiretroviral-naive, HIV-1-infected patients ran-
domised to receive either fosamprenavir-ritonavir 700mg/
100mg twice daily or lopinavir-ritonavir 400mg/100mg
twice daily, each with the coformulation of ABC/3TC. At
week 48, not only the noninferiority of fosamprenavir-
ritonavir to lopinavir-ritonavir (95% CI around the treat-
ment diﬀerence −4.84 to 7.05) was shown, but also the
metabolic impact of the two regimens was comparable [29].
In the CASTLE study, once-daily atazanavir/ritonavir
(n = 440) demonstrated similar antiviral eﬃcacy as twice-
daily lopinavir/ritonavir (n = 443), each combined with
TDF/FTC. Treatment-related gastrointestinal adverse events
were greater in patients taking lopinavir/ritonavir. Mean
changes from baseline in fasting total cholesterol, non-high-
density lipoprotein cholesterol, and triglycerides at week 96
weresigniﬁcantlyhigherwithlopinavir/ritonavir(P<. 0001)
[30].
The ARTEMIS (AntiRetroviral Therapy with TMC114
ExaMined In Naive Subjects) trial, a randomized, open-
label, phase III trial of 689 antiretroviral-naive patients
with HIV-1 RNA at least 5000copies/ml (stratiﬁed by HIV-
1 RNA and CD4 cell count) receiving darunavir/ritonavir
(DRV/r) 800/100mg once daily or lopinavir/ritonavir
(LPV/r) 800/200mg total daily dose (twice daily or once
daily) and TDF/FTC has disclosed 96-week data. DRV/r
patients had smaller median increases in triglycerides (0.1
and 0.6mmol/L, resp.; P<. 0001) and total cholesterol (0.6
and 0.9mmol/L, resp.; P<. 0001) than LPV/r patients; levels
remained below National Cholesterol Education Program
cut-oﬀs for DRV/r. At week 96, once-daily DRV/r was both
statistically noninferior and superior in virologic response
to LPV/r, with a more favorable gastrointestinal and lipid
proﬁle, conﬁrming DRV/r as an eﬀective, well tolerated, and
durable option for antiretroviral-naive patients [31].4 Cholesterol
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Figure 1: Incidence rates of myocardial infarction according to cumulative exposure to nucleoside/nucleotide analogues (A–G), protease
inhibitors (H–K), and nonnucleoside reverse transcriptase inhibitors (L, M). The grey areas indicate the 95% conﬁdence interval. PYFU,
person-years of followup. Adapted from Worm et al. [24].
5. Pharmacologic Management of Dyslipidemia
inHIV-InfectedSubjectson HAART
The Infectious Diseases Society of America (IDSA) and
the European AIDS Clinical Society (EACS) have provided
guidanceforthetreatmentofdyslipidemiaandthereduction
ofcardiovascularriskinpatientswithHIVinfection[32,33].
In general, patients with dyslipidemia and HIV infection
should be treated in a manner similar to the general
population [47, 48]. Statins are recommended for patients6 Cholesterol
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with hypercholesterolemia, although in patients receiving
boosted PIs, they must be used with caution due to the
high risk of interactions. For example, pravastatin levels have
been shown to increase by 81% when given with boosted
darunavir [49], whereas all other PIs tend to lower its levels.
Simvastatin and lovastatin should be avoided in patients
on PI-based regimens given the large and unpredictable
increases in area under the curve (AUC) [50, 51]. NNRTIs,
namely, efavirenz, reduce the blood concentrations of sim-
vastatin and atorvastatin [52]. Until now, pravastatin has
been considered the “safest” to use in combination with
boosted and unboosted PIs. Recently, also rosuvastatin levels
have been shown to increase in HIV-seronegative subjects
who are being treated with LPV/r [53]. In this study, the
LDL-C responses to rosuvastatin during LPV/r coadmin-
istration were diminished despite the higher rosuvastatin
levels observed, suggesting that the drug might be prevented
from reaching the site of action (i.e., by eﬄux pumps). This
observation has been conﬁrmed in HIV-infected patients.
The mean reductions in total cholesterol and LDL-C from
baseline to week 4 on rosuvastatin 10mg once a day were
27.6% and 31.8%, respectively [54]. A large randomized,
double-blind, placebo-controlled, parallel group trial (n =
320) with clinical endpoints is currently ongoing in the
UK, evaluating the eﬃcacy of rosuvastatin in slowing the
progression of the carotid intima-media thickness (C-IMT;
as measured by the change in the mean IMT of the near
and far walls of the distal common carotid arteries), as well
as its impact on hs-CRP, total and fractionated cholesterol,
tryglicerides, and apolipoproteins (APO A1, APO B and
APO B/A1) over 2 years in HIV-infected patients stable on
antiretroviral therapy for at least 12 months having a 10-year
CVD risk lower than 20% (using the Framingham risk score)
[55]. Ezetimibe, a new inhibitor of intestinal absorption of
cholesterol, has been shown to be safe and eﬀective in HIV-
infected patients [56–58].
When hypertriglyceridemia alone is present, often as a
quite common side-eﬀect of boosted PIs, gemﬁbrozil or
fenoﬁbrate are indicated, with minor drug interaction risks
[59, 60]. In some cases of mixed dyslipidemia, associating
a statin and a ﬁbrate may be the best approach for
achieving NCEP ATP III lipid targets in patients with
HIV infection, as shown in a recent study of pravastatin
plus fenoﬁbrate in HIV-infected subjects [61]. Study ACTG
A5087 was a randomized trial of HIV-infected persons
with combined hyperlipidemia who received fenoﬁbrate
or pravastatin monotherapy for 12 weeks followed by the
association of both for up to 48 weeks in case of failure
to meet NCEP goals for LDL-C, HDL-C, and triglyceride
levels. Plasma levels of hs-CRP, lipoprotein particle and
apolipoproteins A1/B, P-selectin (cell adhesion molecule),
plasminogenactivatorinhibitor-1,andadiponectinwerealso
monitored. The majority of subjects (60/74 chosen subjects)
switched to dual therapy at week 12 (n = 32, pravastatin
added to fenoﬁbrate monotherapy and n = 28, fenoﬁbrate
added to pravastatin). Results showed that from baseline
to week 12, adiponectin, apoB levels, and Apo B/A1 ratios
all signiﬁcantly decreased in the pravastatin and fenoﬁbrate
arms, whereas lipoprotein particle and Apo A1 increased
signiﬁcantly in the fenoﬁbrate arm only (P = .01 for both
measures). Combination therapy elicited improvements in
lipid proﬁles without changes in the inﬂammatory and
endothelial cell markers hs-CRP, plasminogen activator
inhibitor-1, and P-selectin. From weeks 12–48, Apo B levels
and Apo B/A1 ratios declined signiﬁcantly in those subjects
adding pravastatin to fenoﬁbrate (P<. 01 and P = .01,
resp.), whereas adiponectin levels signiﬁcantly decreased
in both combination treatment groups. These investigators
suggested that HIV infection or other comorbid infections
may inhibit the anti-inﬂammatory eﬀects associated with
lipid-lowering agents in the general population.
A recent wide retrospective study on 829 patients with
HIV infection and 6941 patients without HIV infection
beginning lipid-lowering therapy for elevated low-density
lipoprotein cholesterol or triglyceride levels from the Kaiser
Permanente Cohort showed that overall the response to
lipid-lowering agents in real life is worse in HIV-infected
subjects. These had had smaller reductions in low-density
lipoprotein cholesterol levels from statin therapy (25.6%
versus 28.3%; P<. 001), which did not vary by antiretroviral
therapyclass.Theyalsoshowedsmallerreductionsintriglyc-
eridelevelsongemﬁbrozilcomparedtopatientswithoutHIV
infection (44.2% versus 59.3%; P .001), and reductions
withgemﬁbrozilvariedbyantiretroviraltherapyclass(44.0%
[P .001] in patients receiving PIs only, 26.4% [P .001] in
patients receiving PIs and nonnucleoside reverse transcrip-
tase inhibitors [NNRTIs], and 60.3% [P .94] in patients
receiving NNRTIs only). Rhabdomyolysis was diagnosed in
3 patients with HIV infection and 1 patient without HIV
infection [62].
HIV-infected subjects often take ﬁsh oil supplements
to control dyslipidemia, and some trials have conﬁrmed
their eﬀect. In the A5186 prospective, phase 2 clinical trial
study on 100 patients, twice-daily administration of ﬁsh
oil supplement or once-daily fenoﬁbrate reduced triglyc-
eride levels by 283mg/dL (46%) and 367mg/dL (58%),
respectively. Patients not responding to single medications
were then treated subsequently with both agents showing a
65.5% reduction from baseline in triglyceride levels. With
the combination therapy, 22.7% achieved triglyceride levels
of ≤200mg/dL, starting from a median level of 667mg/dL
[63]. Lower reduction in serum triglycerides emerged from
another randomized study versus placebo, where ﬁsh oil
supplements at week 8 reduced triglycerides by 25.5% (n =
58) versus 1% in the paraﬃn oil control arm (n =
62). The subsequent open-label phase showed sustained
eﬃcacy through 16-week continued treatment with ﬁsh
oil supplement, while those switched placebo to ﬁsh oil
supplementhada21.2%decreaseinserumtriglycerides[64].
6. Management of Dyslipidemiathrough
Switch Strategies
Another widespread approach among physicians is the
switch to antiretroviral regimens characterized by low
metabolic impact. In recent years, among others, an Italian
team of experts set out recommendations on the diagnosis,8 Cholesterol
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prevention, and treatment of cardiovascular complications
in HIV-infected patients in the HAART era which included
regimen switching rules to reduce the metabolic impact of
drugsavoidingtoexposethepatientstovirologicfailure[65].
Indeed, particularly when substituting high-genetic barrier
drugs such as boosted protease inhibitors, which can even
work in cases of functional or true monotherapy, particular
attention should be paid to the residual eﬃcacy of the
backbone (generally NRTIs), since the new drug would not
have the same features, or, in the case of abacavir, might
be directly aﬀected by resistance to NRTIs. The most lipid-
friendlydrugstoswitchtoareabacavir,tenofovir,nevirapine,
atazanavir, and most recently raltegravir and maraviroc.
Unfortunately abacavir and maraviroc are currently charged
with some suspicion of cardiac toxicity [66, 67]. Trials on the
switch to abacavir have constantly showed signiﬁcant reduc-
tions in total and LDL cholesterol as well as in tryglicerides
[68–70], and whenever patients are accurately selected for
the absence of NRTI resistance-associated mutations or of
previous NRTI failure, this simpliﬁcation does not imply
a higher risk of viral rebound [71]. Unfortunately, some
studies have included patients pretreated with dual NRTI
regimens which, presumably due to baseline resistance,
showed a higher rate of virologic failure (3 versus 0/52 [68]
and 13% versus 10% [72]).
The simpliﬁcation from an eﬀective PI-based regimen to
nevirapine generally proved to be safe and to improve the
lipid proﬁle, although sometimes some degree of hepato-
toxicity was observed [73]. Lypodistrophy, however, is not
reversed by the switch [74]. In a small 24-week insight study
on 55 patients switched from a PI to nevirapine, the lipid
proﬁle improved with a signiﬁcant reduction of apoB (from
0.98 to 0.92g L(-1); P = .005) and triglycerides (from 2.02
to 1.66mmol L(-1); P = .02). HDL cholesterol and apoA1
increased signiﬁcantly (from 0.99 to 1.19mmol L(-1); P =
.001 and from 1.40 to 1.57g L(-1); P<. 001, resp.). The
triglyceride enrichment of HDL signiﬁcantly decreased after
the replacement of PI by nevirapine (from 0.248 +/− 0.092
to 0.213 +/− 0.093; P = .003), leading to a longer HDL half
life. All such changes were correlated with adiponectin levels
[75]. This simpliﬁcation approach has yielded satisfactory
results on the lipid proﬁle of children as well [76]. No
excess failures were reported with nevirapine and in some
cases this strategy maintained better virologic suppression
at 12 months. [73] More recently, switch from efavirenz to
nevirapine has also become a relevant hypothesis, since the
former has always shown to be unable to revert PI-induced
metabolic alterations [77] and has been associated with a
c e r t a i nd e g r e eo fs u c hs i d ee ﬀects. Switching to nevirapine
in such reports was associated with decreases in LDL-
Cholesterol and increases in HDL, as well as with a reduction
of neuropsychiatric eﬀects [40, 78]. Viral suppression was
maintained in all switchers and in one study also two
initially viremic patients suppressed passing to nevirapine
[78].
Switches to tenofovir from thymidine analogues [39],
mainly stavudine [34, 79–81], have showed some good
changesinthelipidproﬁle.Inparticular,astudyon352HIV-
infected subjects followed for 48 weeks found a sustained
reduction in median TC (−17.5mg/dL; P<. 001), LDL-
C( −8.1mg/dL; P<. 001), and TG (−35mg/dL; P<
.001). HDL-C remained roughly unchanged (−0.8mg/dL).
Patients with baseline hyperlipidaemia showed greater
reductions in LDL-C (−29mg/dL; P<. 001) and TG
(−76mg/dL; P<. 001). The greatest TG reduction
was observed in patients with severe hypertrygliceridaemia
(−266mg/dL; P<. 001). The estimated 10-year cardiovascu-
lar risk decreased in all patients (P<. 001) and to a higher
extent in patients with baseline hyperlipidaemia. There was
a trend towards reduction according to the use of lipid-
lowering agents (11.6% to 9,9%; P = nonsigniﬁcant) [35].
However, the beneﬁcial eﬀect sought by many on mitochon-
drial damage and lipodystrophy is still controversial [38, 82],
with the reduction of lactataemia in those patients who
started from elevated serum lactates being the only constant
ﬁnding. This switch provided good metabolic eﬀect also in
children although the data are biased by a contemporary
substitution of efavirenz for PIs [36]. The switch from
thymidine analogues to tenofovir is safe and no virological
failures have been reported in the studies performed up to
date.
In recent years, the most studied simpliﬁcation approach
remains within the family of protease inhibitors and con-
cerns atazanavir, a lipid-friendly compound. All the trials
demonstrated a decline in total cholesterol and tryglicerides,
in particular the large SWAN [37], SLOAT [46], and ATAZIP
trials [44], but when a deeper look was brought, also
H D Lc h o l e s t e r o lt e n d e dt od e c r e a s e[ 45] or remained stable
[83], showing in this respect a diﬀerence from nevirapine
simpliﬁcation. Most recently it has been suggested that even
the low dose ritonavir present in the boosted atazanavir-
based regimens may do or maintain some metabolic harm
and that the switch to unboosted atazanavir in virologically
suppressed patients without resistance-associated mutations
is associated with a more favourable lipid proﬁle without
risks of loosing the grip on HIV, and a large trial seems
to conﬁrm these data [84]. A small pilot study of 9
patients with dyslipidemia and insulin resistance, tested
through hyperinsulinemic euglycemic clamp (insulin dose,
200mU/m minute), showed in all a relevant increase in
insulin sensitivity (+28%; P = .008) 12 months after the
switch from a PI to boosted atazanavir [43]. However,
two studies looked at endothelial function, through the
measurement of the brachial artery ﬂow-mediated dila-
tion and at various inﬂammatory and oxidative stress
markers in subjects switching to boosted atazanavir and
unfortunately found no diﬀerence between baseline and
week 12 and 24 values [85, 86]. Another study looking
at age-related cardiovascular risk found a very limited
impact by this approach, mainly due to the presence of
other relevant and unchanged risk factors [87]. Overall,
simpliﬁcation with atazanavir does not alter viral response,
some studies are showing slightly better control with the
switch and others moderately favour the continuation
arms.
An attempt to exclude nucleoside analogues by building
a PI plus NNRTI regimen in the ACTG 5125 extension trial
maintained viral suppression but worsened the lipid proﬁle10 Cholesterol
of the patients [42]. On the contrary, in the Switchmrk study,
the randomized substitution of lopinavir/ritonavir with the
integrase inhibitor raltegravir yielded an important drop in
serum levels of total cholesterol (−12.6% versus 1.0% in
those who did not switch), non-HDL cholesterol (−15.0%
versus 2.6%), and triglycerides (−42.2% versus 6.2%) in 350
subjects in only 12 weeks [41]. Unfortunately, the inclusion
of patients who did not have a fully eﬀective NRTI backbone
negativelyimpactedontheachievementofthenoninferiority
goal:atweek24,84,4%ofthepatientsswitchedtoraltegravir
maintained a viral load < 50copies/mL versus 90,6% in the
lopinavir continuation arm.
7. Conclusions
CVD risk in HIV infection results from the combination of
theeﬀectsofhostandviralfactorsandantiretroviraltherapy.
Antiretroviral therapy has been shown to reduce HIV-related
inﬂammation, and in some studies also to reduce the impact
ofCVD.Themostrecentrevisionsofinternationalguidelines
for the use of antiretroviral agents have predated the decision
to start therapy at earlier stages of the infection, to reduce
non-HIV-related morbidity and mortality, mainly related to
tumours and CVD.
Understanding the diﬀerences between antiretroviral
drugs with regard to lipid alterations, acceleration of
atherosclerosis, and CVD risk is crucial to plan regimens that
are to be maintained for decades.
The capacity to tailor antiretroviral therapy designed on
individual characteristic and CVD risk proﬁle awaits atten-
tion and ability to balance risk and beneﬁt of antiretroviral
therapy. The clinical impact of the QT prolongation by many
antiretrovirals has not been fully elucidated up to date.
Finally, much work remains to be done in understanding
the mechanisms of the risk posed by therapy and by
HIV itself and the new antiretroviral drugs should not be
considered safe ap r i o r i , as unexpected impact on CVD has
emerged in some cases after many years.
Recently, four new agents from four classes have been
given approval in the US and Canada for use in HIV-infected
persons. Two of these drugs (maraviroc and raltegravir) were
the ﬁrst of their respective classes (integrase inhibitors and
CCR5 inhibitors) to be approved. In addition, another drug,
rilpivirine, is in clinical trial Phase III.
Rilpivirine appears to be associated with lower rates of
lipid elevations than efavirenz; although theoretically the
inhibition of the CCR5 coreceptor seems protective of CVD,
in the MOTIVATE study, the maraviroc arm was associated
with more CVD events.
Raltegravir has not shown up to date any particular
impact on lipids or on CVD, while etravirine and darunavir
also seem more lipid-friendly than many other agents.
However, all these data are theoretical and do not fully
answer to the fundamental question: in future years, starting
therapy earlier, will the balance of CVD in HIV-infected
patients be positive, due to the reduction of HIV-related
damage, or negative, due to the cardiovascular impact of
drugs that we may not fully appreciate today?
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